Literature DB >> 21609375

Hepatic steatosis is not always a contraindication for cadaveric liver transplantation.

Jan P Deroose1, Geert Kazemier, Pieter Zondervan, Jan N M Ijzermans, Herold J Metselaar, Ian P J Alwayn.   

Abstract

BACKGROUND: Macrovesicular steatosis is assumed to be an important risk factor for early allograft dysfunction (EAD) after orthotopic liver transplantation (OLT). AIM: To evaluate the impact of steatosis in combination with other risk factors on the outcome of OLT.
METHODS: The degree of steatosis was analysed in 165 consecutive OLTs and was classified by histological examination as non (M0), mild (<30%, M1), moderate (30-60%, M2) or severe steatosis (>60%, M3). Recipients were analysed for EAD.
RESULTS: EAD was observed in 28% of patients with M0, 26% with M1, 53% with M2 and 73% with M3 (P < 0.001). Patients with EAD had a significantly shorter graft survival after liver transplantation (P = 0.005) but did not correlate with survival. In multivariate regression analysis, the grade of steatosis, donating after cardiocirculatory death (DCD) grafts and duration of cold ischaemia time were significantly associated with EAD (P < 0.001, P = 0.01 and P = 0.001, respectively).
CONCLUSION: Livers with severe (M3) steatosis from DCD donors, combined with a prolonged CIT have a high risk for developing EAD which is correlated with shorter graft survival. Therefore M3 livers should only be considered for OLT in selected recipients without the presence of additional risk factors.
© 2011 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2011        PMID: 21609375      PMCID: PMC3103099          DOI: 10.1111/j.1477-2574.2011.00310.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  33 in total

1.  Use of livers with microvesicular fat safely expands the donor pool.

Authors:  T M Fishbein; M I Fiel; S Emre; O Cubukcu; S R Guy; M E Schwartz; C M Miller; P A Sheiner
Journal:  Transplantation       Date:  1997-07-27       Impact factor: 4.939

2.  Primary nonfunction of hepatic allografts with preexisting fatty infiltration.

Authors:  S Todo; A J Demetris; L Makowka; L Teperman; L Podesta; T Shaver; A Tzakis; T E Starzl
Journal:  Transplantation       Date:  1989-05       Impact factor: 4.939

3.  The outcome of steatotic grafts in liver transplantation.

Authors:  R Adam; M Reynes; M Johann; M Morino; I Astarcioglu; I Kafetzis; D Castaing; H Bismuth
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

4.  Frozen-section diagnosis in donor livers: error rate estimation of steatosis degree.

Authors:  E D'Alessandro; F Calabrese; E Gringeri; M Valente
Journal:  Transplant Proc       Date:  2010 Jul-Aug       Impact factor: 1.066

5.  Survival following liver transplantation from non-heart-beating donors.

Authors:  Peter L Abt; Niraj M Desai; Michael D Crawford; Lisa M Forman; Joseph W Markmann; Kim M Olthoff; James F Markmann
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

6.  Use of fatty donor liver is associated with diminished early patient and graft survival.

Authors:  W A Marsman; R H Wiesner; L Rodriguez; K P Batts; M K Porayko; J E Hay; G J Gores; R A Krom
Journal:  Transplantation       Date:  1996-11-15       Impact factor: 4.939

7.  Donor pool expansion in liver transplantation.

Authors:  R Montalti; B Nardo; R Bertelli; P Beltempo; L Puviani; M Vivarelli; A Cavallari
Journal:  Transplant Proc       Date:  2004-04       Impact factor: 1.066

8.  Impact of steatotic grafts on initial function and prognosis after liver transplantation.

Authors:  R C Afonso; W A Saad; O M Parra; R Leitão; B H Ferraz-Neto
Journal:  Transplant Proc       Date:  2004-05       Impact factor: 1.066

9.  Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation.

Authors:  Deborah Verran; Taras Kusyk; Dorothy Painter; Jodi Fisher; David Koorey; Simone Strasser; Graham Stewart; Geoffery McCaughan
Journal:  Liver Transpl       Date:  2003-05       Impact factor: 5.799

10.  Risk factors for primary dysfunction after liver transplantation--a multivariate analysis.

Authors:  R J Ploeg; A M D'Alessandro; S J Knechtle; M D Stegall; J D Pirsch; R M Hoffmann; T Sasaki; H W Sollinger; F O Belzer; M Kalayoglu
Journal:  Transplantation       Date:  1993-04       Impact factor: 4.939

View more
  17 in total

1.  Guidelines for the assessment and acceptance of potential brain-dead organ donors.

Authors:  Glauco Adrieno Westphal; Valter Duro Garcia; Rafael Lisboa de Souza; Cristiano Augusto Franke; Kalinca Daberkow Vieira; Viviane Renata Zaclikevis Birckholz; Miriam Cristine Machado; Eliana Régia Barbosa de Almeida; Fernando Osni Machado; Luiz Antônio da Costa Sardinha; Raquel Wanzuita; Carlos Eduardo Soares Silvado; Gerson Costa; Vera Braatz; Milton Caldeira Filho; Rodrigo Furtado; Luana Alves Tannous; André Gustavo Neves de Albuquerque; Edson Abdala
Journal:  Rev Bras Ter Intensiva       Date:  2016-09

Review 2.  Using old liver grafts for liver transplantation: where are the limits?

Authors:  Carlos Jiménez-Romero; Oscar Caso Maestro; Félix Cambra Molero; Iago Justo Alonso; Cristina Alegre Torrado; Alejandro Manrique Municio; Jorge Calvo Pulido; Carmelo Loinaz Segurola; Enrique Moreno González
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Minimizing Risks of Liver Transplantation with Steatotic Donor Livers by Preferred Recipient Matching.

Authors:  Kyle R Jackson; Jennifer D Motter; Christine E Haugen; Jane J Long; Betsy King; Benjamin Philosophe; Allan B Massie; Andrew M Cameron; Jacqueline Garonzik-Wang; Dorry L Segev
Journal:  Transplantation       Date:  2019-11-20       Impact factor: 4.939

Review 4.  Liver Transplantation Using Steatotic Grafts.

Authors:  Kyle R Jackson; Jane Long; Benjamin Philosophe; Jacqueline Garonzik-Wang
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-12-20

5.  Clinical Practice Guidelines for Liver Transplantation in Saudi Arabia.

Authors:  Faisal A Abaalkhail; Mohammed I Al Sebayel; Mohammed A Shagrani; Wael A O'Hali; Nasser M Almasri; Abduljaleel A Alalwan; Mohammed Y Alghamdi; Hamad Al-Bahili; Mohammed S AlQahtani; Saleh I Alabbad; Waleed K Al-Hamoudi; Saleh A Alqahtani
Journal:  Saudi Med J       Date:  2021-09       Impact factor: 1.422

Review 6.  Donor Hepatic Steatosis and Outcome After Liver Transplantation: a Systematic Review.

Authors:  Michael J J Chu; Anna J Dare; Anthony R J Phillips; Adam S J R Bartlett
Journal:  J Gastrointest Surg       Date:  2015-04-28       Impact factor: 3.452

7.  Donor Hepatic Steatosis Induce Exacerbated Ischemia-Reperfusion Injury Through Activation of Innate Immune Response Molecular Pathways.

Authors:  Ricardo C Gehrau; Valeria R Mas; Catherine I Dumur; Jihee L Suh; Ashish K Sharma; Helen P Cathro; Daniel G Maluf
Journal:  Transplantation       Date:  2015-12       Impact factor: 4.939

Review 8.  Liver cell therapy: is this the end of the beginning?

Authors:  Salamah M Alwahsh; Hassan Rashidi; David C Hay
Journal:  Cell Mol Life Sci       Date:  2017-11-27       Impact factor: 9.261

9.  Prevalence of Steatosis Hepatis in the Eurotransplant Region: Impact on Graft Acceptance Rates.

Authors:  Simon Moosburner; Joseph M G V Gassner; Maximilian Nösser; Julian Pohl; David Wyrwal; Felix Claussen; Paul V Ritschl; Duska Dragun; Johann Pratschke; Igor M Sauer; Nathanael Raschzok
Journal:  HPB Surg       Date:  2018-11-01

10.  Minimizing Risks of Liver Transplantation With Steatotic Donor Livers by Preferred Recipient Matching.

Authors:  Kyle R Jackson; Jennifer D Motter; Christine E Haugen; Jane J Long; Betsy King; Benjamin Philosophe; Allan B Massie; Andrew M Cameron; Jacqueline Garonzik-Wang; Dorry L Segev
Journal:  Transplantation       Date:  2020-08       Impact factor: 5.385

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.